(Q38752448)

6 September 2017

Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. (English)

1 reference

6 September 2017

0 references

1 reference

hepatocellular carcinoma

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921078%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Helen L Reeves

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921078%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Christopher P Day

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921078%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

26 February 2016

1 reference

Digestive Diseases and Sciences

6 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921078%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

61

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921078%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921078%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

1234-1245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26921078%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10620-016-4085-6

31 May 2020

exact match

0 references

cites work

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Obesity and cancer risk: a Danish record-linkage study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

A prospective study of obesity and cancer risk (Sweden).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Diabetes and cancer: a consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The changing pattern of epidemiology in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Population-based risk factors and resource utilization for HCC: US perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The liver and the waistline: Fifty years of growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Genetic modifiers of non-alcoholic fatty liver disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

A fresh look at NASH pathogenesis. Part 1: the metabolic movers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Genetics of alcoholic and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Fate of fat: the role of adipose triglyceride lipase in lipolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Non-alcoholic fatty liver disease from pathogenesis to management: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Abnormalities of lipid metabolism in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Diabetes and cancer: epidemiology and potential mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Biological mechanisms linking obesity and cancer risk: new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Role of hypoxia in the hallmarks of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Obstructive sleep apnea syndrome and fatty liver: association or causal link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Obesity is associated with macrophage accumulation in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Fibrosis and adipose tissue dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Macrophages, immunity, and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Macrophages, inflammation, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Endocrinology of adipose tissue - an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Positional cloning of the mouse obese gene and its human homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Hyperleptinaemia: the missing link in the, metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Leptin Levels in Type 2 Diabetes: Associations with Measures of Insulin Resistance and Insulin Secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Leptin in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The role of adiponectin in cancer: a review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Adipokines in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Metabolic regulation of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

T lymphopenia in genetically obese-diabetic Wistar fatty rats: effects of body weight reduction on T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Impairment of dendritic cell functionality and steady-state number in obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Obesity and immunocompetence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Obesity is associated with impaired immune response to influenza vaccination in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The microbiome and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The gut microbiota, bacterial metabolites and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Mechanisms of disease progression in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Sterile inflammation in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Neutrophils and intravascular immunity in the liver during infection and sterile inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

NFκB1 is a suppressor of neutrophil-driven hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Altered profile of human gut microbiome is associated with cirrhosis and its complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Gut microbiota and non-alcoholic fatty liver disease: new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Bile Acid Receptors and Liver Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Regulation of mammalian autophagy in physiology and pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Autophagy regulates lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Obesity, autophagy and the pathogenesis of liver and pancreatic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

The Role of Autophagy in Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Functions of autophagy in normal and diseased liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Decoding cell death signals in liver inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Amphiregulin activates human hepatic stellate cells and is upregulated in non alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

MicroRNAs in Liver Disease: Bench to Bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

miRNA in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Hepatocellular carcinoma and lifestyles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Mediterranean diet and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Statin use and non-alcoholic steatohepatitis in at risk individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-016-4085-6

Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease

1 reference

12 December 2020

Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis

1 reference

12 December 2020

The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1

1 reference

12 December 2020

Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds

1 reference

12 December 2020

NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States

1 reference

12 December 2020

Terminology of nodular hepatocellular lesions.

1 reference

12 December 2020

Role of leptin and its receptors in the pathogenesis of thyroid cancer

1 reference

12 December 2020

Anti-cancer activities of ω-6 polyunsaturated fatty acids

1 reference

12 December 2020

Prevalence and markers of advanced liver disease in type 2 diabetes

1 reference

12 December 2020